Viewing Study NCT06898957


Ignite Creation Date: 2025-12-24 @ 6:44 PM
Ignite Modification Date: 2026-01-01 @ 7:22 PM
Study NCT ID: NCT06898957
Status: RECRUITING
Last Update Posted: 2025-12-05
First Post: 2025-03-21
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Sponsor: Amgen
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module